Long acting GLP-1 receptor agonist (injectable)
TG103 22.5 mg injection once weekly
TG103_SC_22p5MG_QW
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Overweight or obesity without diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 0.70 (0.01 to 55.00) | 0.57 |
| Overweight or obesity without diabetes (adults) | Discontinuation due to adverse events | longest follow-up | Placebo | HR 0.69 (0.01 to 56.45) | 0.64 |
| Overweight or obesity without diabetes (adults) | Nausea | longest follow-up | Placebo | HR 13.16 (2.86 to 91.77) | 0.12 |
| Overweight or obesity without diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 5.85 (0.88 to 51.44) | 0.40 |
| Overweight or obesity without diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 4.52 (0.96 to 26.22) | 0.22 |
| Overweight or obesity without diabetes (adults) | Discontinuation due to gastrointestinal adverse events | longest follow-up | Placebo | HR 0.66 (0.01 to 56.03) | 0.65 |